Zero Gravity Solutions nearing goal for stock trade
Zero Gravity Solutions, Inc. announced Thursday that it has completed the filings required to satisfy the financial reporting necessary to commence the trading of the Company’s stock under the trading symbol ZGSI.PK.
“Our business model for Zero Gravity Solutions is to ultimately patent and license these non-GMO stem cells for commercial use which can produce royalty revenue that represents a recurring revenue stream.”
Zero Gravity Solutions, Inc., a biotechnology company, aims to utilize the unique effects of extended zero/micro gravity environments only available on the International Space Station (“ISS”), now a national lab. The Company’s intellectual property was developed and validated through six NASA-enabled flights to the ISS under the Company’s Space Act Agreement. ZGSI’s intellectual property is based upon the premise that genes and cells express differently in a zero/microgravity environment, allowing for the development of patentable plant, animal and human regenerative stem cells with unique and beneficial characteristics.
The company has assembled a highly knowledgeable and experienced group of business and financial professionals as well as well-known and respected scientific leaders in applied research relating to ZGSI’s core commercialization opportunities. The work of these scientific leaders has an emphasis on the effects of zero/micro gravity on cash crops, alternative energy cash crops and human regenerative medicine.
Richard Godwin, Zero Gravity Solutions, Inc.’s president and chief executive officer stated, “Based upon my 20 years of involvement in various aspects of the US space program, it is clear to me that a central focus of NASA and CASIS today is to accelerate the commercial use of the International Space Station. We believe the Company can earn money by performing applied research that can only be done on the ISS: Exposing stem cells to extended microgravity to promote gene expression that can result in new varieties of stem cells with commercial applications. Our business model for Zero Gravity Solutions is to ultimately patent and license these non-GMO stem cells for commercial use which can produce royalty revenue that represents a recurring revenue stream.”
Source: Zero Gravity Solutions, Inc.